Here is the design of a clinical trial:

Official Title: Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection: a Randomized, Double-blind, Placebo-controlled Trial

Included conditions:
- Clostridioides Difficile Infection
- Clostridium Difficile Infection
- Clostridium Difficile Diarrhea
- Clostridia Difficile Colitis

Study Armgroups:
- {'label': 'Alanyl-glutamine 0g', 'type': 'PLACEBO_COMPARATOR', 'interventionNames': ['Drug: Alanyl-glutamine']}
- {'label': 'Alanyl-glutamine 4g', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: Alanyl-glutamine']}
- {'label': 'Alanyl-glutamine 24g', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: Alanyl-glutamine']}
- {'label': 'Alanyl-glutamine 44g', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: Alanyl-glutamine']}

Interventions:
- {'type': 'DRUG', 'name': 'Alanyl-glutamine', 'description': 'The study agent is AQ, a dipeptide with a glutamine amino group joined to an alanyl residue. It has the following chemical structure: C8H15N3O4. It is a non-animal product available in the form of white crystals or crystalline powder. It is odorless, tasteless, stable and highly soluble.', 'armGroupLabels': ['Alanyl-glutamine 0g', 'Alanyl-glutamine 24g', 'Alanyl-glutamine 44g', 'Alanyl-glutamine 4g'], 'otherNames': ['Alagln', 'AQ', 'glutamine']}

Primary Outcomes:
- {'measure': 'Number of participants with recurrent CDI.', 'description': 'Documented C difficile infection defined by presence of recurrent diarrhea with stool positive for C difficile assay necessitating treatment with anti-C. difficile antibiotic.', 'timeFrame': 'Within 60 days post-treatment'}

Please estimate the sample size based on the assumption: 
Alpha level of 0.05, power of 90%, 17% mortality during 60 days post-treatment follow-up, and a loss of 60-days follow-up rate not more than 10%.
Sample size justification
        Sample size estimations are based on the presence of four study groups (placebo, 4âmg dose, 24âmg dose and 44âmg dose), a 40% recurrence rate of CDI in the standard treatment control arm (placebo) with a 15% difference between best intervention and the standard control treatment, alpha level of 0.05 and power of 90%. With these specifications, 59 participants per group (total n=236) are required using a single stage approach for randomised phase II trial designs with multiple groups. Fifty-nine persons per group will also achieve 80% power for a minimum difference of 12%. Assuming a 17% mortality during 60 days post-treatment follow-up in this population, the proposed sample size of 236 provides 90% power for a minimum detectable difference of 10% in mortality between the active treatment groups and control group. Assuming a loss of 60-days follow-up rate not more than 10%, 260 participants (65 persons per group) will be required to meet our primary objectives.